MedTrace Logo

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

NCT07568756 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-06

No results posted yet for this study

Summary

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Flotufolastat F18 PET

Flotufolastat F18 PET

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Michael Daneshvar, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-05-31
Completion
2029-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07568756 on ClinicalTrials.gov